The complement inhibitors in COVID-19: Future expectations

[No abstract available]

Authors
Korotchaeva Y. 1 , Kozlovskaya N. 2 , Bobrova L. 1 , Kamyshova E. 1 , Demyanova K. 2 , Moiseev S. 1
Journal
European Review for Medical and Pharmacological Sciences
Publisher
Verduci Editore
Issue number
12
Language
English
Pages
6480-6481
State
Published
Link
External link
DOI
10.26355/EURREV_202006_21628
Volume
24
Year
2020
Organizations
  • 1 Sechenov First Moscow State Medical University, Moscow, Russian Federation
  • 2 Peoples' Friendship University of Russia, Moscow, Russian Federation
Keywords
complement component C5a; complement inhibitor; eculizumab; complement inhibitor; eculizumab; monoclonal antibody; adult respiratory distress syndrome; coronavirus disease 2019; cytokine storm; disease predisposition; disease severity; drug efficacy; drug inhibition; heredity; human; infection risk; Letter; lung biopsy; lung injury; multiple organ failure; mutation; nonhuman; prediction; protein blood level; Severe acute respiratory syndrome coronavirus 2; thrombotic thrombocytopenic purpura; treatment duration; Betacoronavirus; Coronavirus infection; motivation; pandemic; virus pneumonia; Antibodies, Monoclonal, Humanized; Betacoronavirus; Complement Inactivating Agents; Coronavirus Infections; Humans; Motivation; Pandemics; Pneumonia, Viral
Cite
ГОСТ MLA RIS BibTex
Share

Other records